Sponsored by
This new study from Japan provides further evidence in favor of adaptive radiation therapy (ART) for glioblastoma (GBM). The ART approach adjusts the radiation plan during treatment based on changes in the tumor or surgical cavity. In 59 GBM patients, ART was safe and showed promising outcomes: median overall survival was about 27 months, progression-free survival about 10 months, and serious radiation side effects were rare. While research on ART in brain cancer is still developing, it does provide hope that smarter, adaptable radiation plans could help patients live longer with fewer side effects.